Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 10/20 | 0.83 |
| ▸ | CYSLTR2 | Q9NS75 | 5/20 | 0.83 |
| ▸ | GRM2 | Q14416 | 15/20 | 0.80 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | GLA | P06280 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.64 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29466707 | 0.87 | GRM2 (1.00) | CYSLTR1CYSLTR2GRM2MEN1LMNA | |
| SCHEMBL6245198 | 0.87 | GRM2 (1.00) | CYSLTR1CYSLTR2GRM2MEN1LMNA | |
| SCHEMBL8337653 | 0.86 | GRM2 (1.00) | CYSLTR1CYSLTR2GRM2MEN1LMNA | |
| SCHEMBL8337474 | 0.86 | GRM2 (0.94) | CYSLTR1CYSLTR2GRM2MEN1LMNA | |
| SCHEMBL3157609 | 0.86 | CYSLTR1 (0.89) | CYSLTR1CYSLTR2GRM2 | |
| SCHEMBL3166625 | 0.85 | CYSLTR1 (0.88) | CYSLTR1CYSLTR2GRM2 | |
| SCHEMBL481058 | 0.85 | CYSLTR1 (0.88) | CYSLTR1CYSLTR2GRM2 | |
| SCHEMBL6245759 | 0.84 | CYSLTR1 (0.59) | CYSLTR1CYSLTR2GRM2MEN1TSHR | |
| SCHEMBL6243450 | 0.84 | GRM2 (0.80) | CYSLTR1CYSLTR2GRM2MEN1LMNA | |
| SCHEMBL6246394 | 0.83 | GRM2 (1.00) | CYSLTR1CYSLTR2GRM2MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288346-A1 | Acetophenone potentiators of metabotropic glutamate receptors | MERCK & CO., INC. | 2005-12-29 | — | — | US | disclosed |
| EP-1556038-A2 | ACETOPHENONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Merck & Co., Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004018386-A2 | ACETOPHENONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK & CO., INC. (US) | 2004-03-04 | — | — | WO | disclosed |
| WO-2004018386-A2 | ACETOPHENONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK & CO., INC. (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288346-A1 | Acetophenone potentiators of metabotropic glutamate receptors | GRM2, GRM1, GRIK2 | CYSLTR1 429/4885CYSLTR2 357/4885GRM2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.